Plasma autoantibody biomarkers for basal like breast cancer

US11525831B2 · kind B2 · utility

Assignees

• ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Joshua LaBaer · Chandler, US
• Jie Wang · Lake Bluff, US
• Ji Qui · Chandler, US
• Garrick Wallstrom · Mesa, US
• Karen Anderson · Guilford, US
• Jin Park · Phoenix, US
• Jonine Figueroa · Edinburgh, GB

Key dates

• Filing date: Jan 15, 2020
• Grant date: Dec 13, 2022
• Expiry date: May 6, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).